Oncternal Therapeutics Inc 's ROA from the third quarter of 2024 to the third quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Oncternal Therapeutics Inc 's ROA in the third quarter of 2024?
Oncternal Therapeutics Inc recorded a cumulative net loss of $-35 million during 12 months ending in the third quarter of 2024, resulting in a negative return on assets (ROA) of -131.3%.

However, within the Healthcare sector 877 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the second quarter of 2024 from 4687 to 4723.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter
Y / Y Total Assets Change	-63.88 %	-53.01 %	-50 %	-46.22 %	-43.29 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-35	-36	-36	-39	-42
Return On Assets (TTM)	-131.3 %	-108.25 %	-91.04 %	-83.56 %	-75.66 %
ONCT's Total Ranking	# 4723	# 4687	# 4680	# 5356	# 4751
Total Assets (TTM) in million	16	24	29	37	43
Seq. Total Assets Change	-34.61 %	-18.13 %	-20.66 %	-14.97 %	-14.93 %
Seq. Net Income Change	-	-	-	-	-

ONCT's 5 Years Annual ROA >> Back to ONCT Management Effectiveness >> Compare ONCT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 421
Sector	# 878
Overall	# 4632

Return On Assets Statistics
High	Average	Low
93.47 %	-78.34 %	-184.57 %
(Jun 30 2016)		(Jun 30 2015)

Financial Statements
Oncternal Therapeutics Inc 's Assets	$ 16 million	ONCT's Balance sheet
Oncternal Therapeutics Inc 's Income	$ -8 million	Quarterly ONCT's Income Statement
ONCT's Income by Division		See ONCT's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019
Y / Y Total Assets Change	-46.22 %	-27.03 %	-21.23 %	446.4 %	-30.58 %
Total Assets in million	37	68	94	119	22
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-39	-44	-31	-17	-34
Annual Return On Assets	-107.49 %	-64.68 %	-33.48 %	-14.5 %	-157.23 %

ONCT's 5 Years Annual ROA >> Back to ONCT Management Effectiveness >> Compare ONCT ROA to its Competitors

More Return On Assets Ratios
ONCT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ONCT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ONCT's Competitors
Subscribers only: Roa for Oncternal Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for ONCT's Customers

You may also want to know
ONCT's Roi	ONCT's Inventory Turnover Ratio	ONCT's Growth Rates	ONCT's Dividend Comparisons
	ONCT's Profitability Ratios	ONCT's Asset Turnover Ratio	ONCT's Dividend Growth
ONCT's Roe	ONCT's Valuation Ratios	ONCT's Financial Strength Ratios	ONCT's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2024, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:27:14+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.